From Recent Issues

Functional Dyspepsia: A Review of the Symptoms, Evaluation, and Treatment Options

  Abstract: The community prevalence of dyspepsia ranges from 20% to 40%, and dyspepsia accounts for 3% to 5% of primary care visits. Dyspepsia symptoms include […]

Vedolizumab-Induced De Novo Extraintestinal Manifestations

  Abstract: Background: Vedolizumab is an α4β7 integrin antagonist with gut-specific effects on lymphocyte and monocyte trafficking. Although the treatment is beneficial for inflammatory bowel disease (IBD), […]

Diagnostic Testing for Barrett Esophagus

  G&H  What is the importance of Barrett esophagus in relation to esophageal cancer? PS  Barrett esophagus is the only known premalignant condition of esophageal adenocarcinoma, […]


Highlights From the 2019 Advances in Inflammatory Bowel Diseases Conference

A Review of Selected Presentations From the 2019 AIBD Conference • December 12-14, 2019 • Orlando, Florida   A Practical Approach to Anti-Interleukins in IBD 2020 […]

Highlights in IBD From the American College of Gastroenterology 2019 Annual Scientific Meeting and United European Gastroenterology Week 2019

A Review of Selected Presentations From the ACG 2019 Meeting • October 25-30, 2019 • San Antonio, Texas and UEG Week 2019 • October 19-23, 2019 […]

Highlights in the Management of Ulcerative Colitis and Crohn’s Disease From the 2019 Digestive Disease Week Meeting

A Review of Selected Presentations From the 2019 DDW Meeting • May 18-21, 2019 • San Diego, California   Vedolizumab Shows Superior Efficacy Versus Adalimumab: Results […]

Millennium Medical Publishing, Inc